{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:55:25Z","timestamp":1790477725368,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2019-000611","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T05:55:36Z","timestamp":1579586136000},"page":"e000611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["EHA evaluation of the ESMO\u2014Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-2371","authenticated-orcid":false,"given":"Barbara","family":"Kiesewetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan I.","family":"Cherny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cerisoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urania","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Huntly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Jane","family":"Latino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mr\u00eda-Victoria.","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Zygoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000611_bb0010","first-page":"253","article-title":"Value frameworks in oncology: comparative analysis and implications to the pharmaceutical industry","volume":"10","author":"Slomiany","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1136\/esmoopen-2019-000611_bb0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.18.00729","article-title":"Comparative assessment of clinical benefit using the ESMO-Magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score","volume":"37","author":"Cherny","year":"2019","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology magnitude of clinical benefit scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0025","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/bmj.321.7272.1300","article-title":"Accountability for Reasonableness","volume":"321","author":"Daniels","year":"2000","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000611_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02344674","article-title":"Decisions about access to health care and accountability for Reasonableness","volume":"76","author":"Daniels","year":"1999","journal-title":"J Urban Health"},{"key":"10.1136\/esmoopen-2019-000611_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000216","article-title":"Detailed statistical assessment of the characteristics of the ESMO magnitude of clinical benefit scale (ESMO-MCBS) threshold rules","volume":"2","author":"Dafni","year":"2017","journal-title":"ESMO Open"},{"key":"10.1136\/esmoopen-2019-000611_bb0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14737167.2017.1343146","article-title":"The ESMO-Magnitude of clinical benefit scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel","volume":"18","author":"Hammerman","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1136\/esmoopen-2019-000611_bb0050","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1093\/annonc\/mdw297","article-title":"Utilisation of the ESMO-MCBS in practice of HTa: table 1","volume":"27","author":"Wild","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0060","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0065","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0075","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0080","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0090","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0095","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-Related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0105","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-Reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2019-000611_bb0110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia Chromosome\u2013Positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0125","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-Term remissions after FcR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2016.1190966","article-title":"Fcr front-line therapy and quality of life in patients with chronic lymphocytic leukemia","volume":"58","author":"Kutsch","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2019-000611_bb0140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-Line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0145","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2016.07.066","article-title":"Analysis of quality of life and well-being from the randomized phase 3 study of ibrutinib versus chlorambucil in older patients with treatment-na\u00efve CLL (RESONATE-2TM)","volume":"16","author":"Kipps","year":"2016","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0155","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0170","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0175","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0185","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0190","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the iris study","volume":"21","author":"Hahn","year":"2003","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0195","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0200","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0205","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-Term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0210","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0215","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0225","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/cncr.29053","article-title":"Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules","volume":"121","author":"Guilhot","year":"2015","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2019-000611_bb0230","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0235","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0240","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0245","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0250","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the bright study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0255","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in quality of life between Bendamustine-Rituximab and R-CHOP\/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0260","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0265","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00277-016-2878-5","article-title":"Health-Related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","volume":"96","author":"Cheson","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1136\/esmoopen-2019-000611_bb0275","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with Rituximab-Refractory indolent non-Hodgkin lymphoma who received Obinutuzumab plus bendamustine induction and Obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0280","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; sprint): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0290","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting Btk with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0295","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0300","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"Pi3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0305","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0310","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0315","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0320","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MINT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0325","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MINT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0330","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-Term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0335","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"Chop chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0340","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0345","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0350","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0355","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0360","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0365","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2019-000611_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0375","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0380","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0385","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0390","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0395","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (pad) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0400","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0405","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0410","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0415","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0420","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0425","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0430","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0435","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/esmoopen-2019-000611_bb0440","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-Related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0445","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0450","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0455","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4\u2010year follow\u2010up and analysis of relative progression\u2010free survival from the randomized ELOQUENT\u20102 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2019-000611_bb0460","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0465","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the apex trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0470","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0475","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (endeavor): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0480","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood.V128.22.3309.3309","article-title":"Health related quality of life results from the open-label, randomized, phase III endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"128","author":"Ludwig","year":"2016","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0485","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0490","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2019-000611_bb0495","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0500","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0505","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0510","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (Sirius): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2019-000611_bb0515","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000611_bb0520","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0525","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood-2017-05-782961","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma","volume":"130","author":"Paludo","year":"2017","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0530","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000611_bb0535","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2019-000611_bb0540","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0545","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents","volume":"34","author":"Santini","year":"2016","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0550","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive Care\u2014SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000611_bb0555","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Ferrini","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1136\/esmoopen-2019-000611_bb0560","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1136\/esmoopen-2019-000611_bb0565","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the eastern cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0570","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000611_bb0575","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000611_bb0580","unstructured":"European Hematology Association. Available:https:\/\/ehaweb.org\/"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:30Z","timestamp":1761855870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920300156"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000611","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EHA evaluation of the ESMO\u2014Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000611"}}